CRISPR and Genome Editing – News and Features

Penn researchers introduce mvGPT, a gene editing tool that edits DNA, activates genes and represses gene expression simultaneously. Successfully tested on cells with Wilson’s disease, mvGPT addresses multiple conditions with high precision.

Rutgers researchers highlight the role of brown adipose tissue (BAT) in boosting endurance and promoting healthy aging. BAT improves blood circulation, reduces cellular stress and enhances metabolism

ECRC researchers developed a CRISPR-based gene therapy targeting dysferlin mutations in muscular dystrophy. By editing and transplanting corrected muscle stem cells, they restored protein function and regrew muscle in preclinical models.

This article provides examples of where AI has been utilized to predict disease outbreaks and how AI models could help inform future strategies for controlling the spread of infectious diseases.

New research by Oregon Health & Science University scientists has uncovered multiple factors to improve gene delivery to the kidney by adeno-associated virus vectors.

St. Jude researchers developed a 3D atlas tracing brain connections to spinal V1 interneurons, crucial for movement. Using modified rabies virus and serial two-photon tomography, they mapped neural pathways for motor control.

University of Illinois researchers developed SPLICER, a gene editing tool enhancing exon skipping. Targeting Alzheimer’s-related genes in mice, SPLICER decreased amyloid-beta plaque precursors by 25%, outperforming CRISPR techniques.

The findings reveal that climate change and measures to control populations of tsetse flies, which carry the disease, may drive molecular changes in the organisms that cause sleeping sickness – which can be fatal if left untreated.

A chemogenetic tool could form the basis of a gene therapy for chronic pain by turning off pain receptors.

McGill researchers discovered that K884, an experimental drug, enhances muscle stem cell repair in Duchenne muscular dystrophy (DMD). Unlike gene therapies, K884 targets DMD-affected cells regardless of the mutation.